98%
921
2 minutes
20
Objective: To determine the effect of differences in the distances and radial positions of the tips of Light-Curing Units (LCU) on the irradiance values delivered.
Materials And Methods: Four LCUs-Valo X, Emitter A, CuringPen, and Pinkwave were tested at different distances from the tip (0, 2, 4, 6, 8 mm) and radial displacements (2 and 4 mm East, West, North, South). The radiant power (mW) and emission spectrum (mW/nm) were measured using an integrating sphere with a 4 mm aperture. Calibrated irradiance beam profiles were recorded across the tip using a laser beam analyzer. Data were analyzed with a two-way ANOVA at a significance level of 5%.
Results: Radial displacement significantly reduced the irradiance values delivered from all four LCUs (p < 0.05). At 4 mm, the mean irradiance value was below 1000 mW/cm for Emitter A (256 mW/cm), CuringPen (573 mW/cm), and Valo X (955 mW/cm), but not for the Pinkwave (1157 mW/cm). At the 2 and 4 mm distance from the tip, the Valo X delivered consistent mean irradiance values at both the center and radial positions (2 mm: 1120 mW/cm and 1089 mW/cm; 4 mm: 979 mW/cm and 945 mW/cm, p > 0.05). The Valo X emitted the most homogeneous beam profile, irrespective of the distance.
Conclusion: Variations of 2 or 4 mm in the radial tip position negatively affected irradiance values from the LCUs tested.
Clinical Significance: The radial position and LCU choice can significantly affect the irradiance delivered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jerd.70011 | DOI Listing |
Appl Biosaf
August 2025
Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.
Background: Serum and other blood-derived products are widely used in biomedical and biopharmaceutical processes, especially for the production of vaccines or cell therapeutic applications. To ensure quality and safety, each serum lot undergoes testing for sterility to minimize the risk of disease transmission. A currently performed standard procedure is gamma-irradiation of serum for effectively killing pathogens.
View Article and Find Full Text PDFMed Phys
September 2025
Department of Accelerator and Medical Physics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Background: Multi-ion radiotherapy using carbon, oxygen, and neon ions aims to improve local control by increasing dose-averaged linear energy transfer (LET) in the target. However, there has been limited understanding of how to utilize variables for multi-ion treatment planning such as the selection and arrangement of ion species.
Purpose: An in silico study was conducted to explore the feasibility of increasing a minimum LET, and the optimal selection and arrangement of ion species in multi-ion therapy for increasing LET in tumors of varying sizes mimicking bone and soft tissue sarcomas (BSTS).
Med Phys
September 2025
Medical Physics Unit, Department of Oncology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Background: Se ( 120 days, 215 keV) offers advantages over Ir ( 74 days, 360 keV) as a high dose rate brachytherapy source due to its lower gamma energy and longer half-life. Despite its widespread use in industrial gamma radiography, a Se brachytherapy source has yet to be manufactured.
Purpose: A novel Se-based source design with a vanadium diselenide core, titled the SeCure source, was proposed.
J Appl Clin Med Phys
September 2025
Department of Radiation Oncology, Virginia Commonwealth University, Richmond, Virginia, USA.
Purpose: Real‑time magnetic resonance-guided radiation therapy (MRgRT) integrates MRI with a linear accelerator (Linac) for gating and adaptive radiotherapy, which requires robust image‑quality assurance over a large field of view (FOV). Specialized phantoms capable of accommodating this extensive FOV are therefore essential. This study compares the performance of four commercial MRI phantoms on a 0.
View Article and Find Full Text PDFInt J Gynecol Cancer
August 2025
12 de Octubre University Hospital, Medical Oncology Department, Madrid, Spain.
Objective: The value of progression-free survival as a surrogate marker for overall survival remains a matter of debate. Herein, we evaluated the validity of progression-free survival as a surrogate endpoint for overall survival in trials of recurrent or metastatic endometrial cancer.
Methods: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.